- Home
- PTGX vs CYTK Comparison
PTGX vs CYTK Comparison
Compare PTGX & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- CYTK
- Stock Information
- Founded
- PTGX 2006
- CYTK 1997
- Country
- PTGX United States
- CYTK United States
- Employees
- PTGX N/A
- CYTK N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- CYTK Health Care
- Exchange
- PTGX Nasdaq
- CYTK Nasdaq
- Market Cap
- PTGX 4.0B
- CYTK 4.6B
- IPO Year
- PTGX 2016
- CYTK 2004
- Fundamental
- Price
- PTGX $76.75
- CYTK $61.61
- Analyst Decision
- PTGX Strong Buy
- CYTK Strong Buy
- Analyst Count
- PTGX 9
- CYTK 15
- Target Price
- PTGX $78.11
- CYTK $76.73
- AVG Volume (30 Days)
- PTGX 1.5M
- CYTK 1.8M
- Earning Date
- PTGX 10-31-2025
- CYTK 11-05-2025
- Dividend Yield
- PTGX N/A
- CYTK N/A
- EPS Growth
- PTGX N/A
- CYTK N/A
- EPS
- PTGX 0.80
- CYTK N/A
- Revenue
- PTGX $209,180,000.00
- CYTK $85,738,000.00
- Revenue This Year
- PTGX N/A
- CYTK $363.61
- Revenue Next Year
- PTGX $142.86
- CYTK $64.08
- P/E Ratio
- PTGX $95.33
- CYTK N/A
- Revenue Growth
- PTGX N/A
- CYTK 2635.74
- 52 Week Low
- PTGX $33.31
- CYTK $29.31
- 52 Week High
- PTGX $93.25
- CYTK $63.86
- Technical
- Relative Strength Index (RSI)
- PTGX 59.19
- CYTK 62.51
- Support Level
- PTGX $73.08
- CYTK $54.30
- Resistance Level
- PTGX $79.00
- CYTK $63.22
- Average True Range (ATR)
- PTGX 2.93
- CYTK 2.45
- MACD
- PTGX -0.37
- CYTK -0.19
- Stochastic Oscillator
- PTGX 27.14
- CYTK 76.41
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.